Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced the Phase I/II LENTICLAIR 1 trial of inhaled lentiviral vector-based gene ...
Viral Vector And Plasmid DNA Manufacturing Market size to Show Positive Growth at a CAGR of ...
The global viral vector and plasmid DNA manufacturing market size is calculated at USD 8.66 billion in 2025 and is expected ...